Your browser doesn't support javascript.
loading
Self-reported COPD Medication Use and Adherence in the COPD Foundation Patient- Powered Registry Network.
Pasquale, Cara B; Choate, Radmila; McCreary, Gretchen; Mularski, Richard A; Clark, William; Houlihan, MaryEllen; Malanga, Elisha; Yawn, Barbara P.
Afiliação
  • Pasquale CB; COPD Foundation, Inc, Washington, DC, United States.
  • Choate R; COPD Foundation, Inc, Washington, DC, United States.
  • McCreary G; Department of Epidemiology, College of Public Health University of Kentucky, Lexington, Kentucky, United States.
  • Mularski RA; COPD Foundation, Inc, Washington, DC, United States.
  • Clark W; Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, United States.
  • Houlihan M; Oregon Health & Science University, Portland, Oregon, United States.
  • Malanga E; Center for Ethics in Health Care, Oregon Health & Science University, Clackamas, Oregon, United States.
  • Yawn BP; COPD Foundation, Inc, Washington, DC, United States.
Chronic Obstr Pulm Dis ; 8(4): 474-487, 2021 Oct 28.
Article em En | MEDLINE | ID: mdl-34496465
ABSTRACT

PURPOSE:

Pharmacotherapy is one cornerstone of Chronic Obstructive Pulmonary Disease (COPD) management. Published U.S. data seldom includes patient-reported COPD medication use and adherence. We add this patient perspective to the commonly reported administrative prescribing and fill data.

METHODS:

This survey study used inhaler and nebulizer pictures and lists of oral COPD medications to query members of the COPD Foundation Patient-Powered Research Network, a national self-reported online registry. Medications used, adherence, inhaler education, cost concerns, previous exacerbations, and COPD Assessment Test scores were assessed and summarized using simple descriptive statistics and hazard ratios controlling for age, gender, and disease burden.

RESULTS:

Respondents mean age was 68 years, 60% were women, >69% with the COPD Assessment Test (CAT) scores >15, and >50% reported 2 or more exacerbations in the past 12 months. Overall, >98% used one or more inhaled COPD medications, 7.6% rescue inhaler only, 17.8% used long-acting bronchodilator only therapy (11.1% dual), and 72.8% using corticosteroid therapies, including 53% triple therapy. Nebulizers were used by 59.4% and 34.8% use oral COPD medications. Reported adherence rates were high (80.1%), but 41% reported trouble paying for medications, with 20.1% reported missing medications due to cost.

CONCLUSIONS:

In this population, COPD had a high burden with >50% of respondents using triple therapy, and one in eight maintenance oral corticosteroids. Self-reported adherence was high, but with significant cost concerns reported resulting in missed medications.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article